Trial Profile
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Pembrolizumab (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 08 Jun 2021 Status changed to discontinued , according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 The first 4 patients received vem/pembro and the protocol was subsequently amended, and next 5 patients received vem/cobi/pembro.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology